New Faces of Immunotherapy

[vc_row][vc_column][vc_column_text]Immunotherapy is changing cancer as we know it. Experts predict that in just 10 years, immunotherapy will form the backbone for over 60% of cancer treatments, as opposed to less than 3% today.

As the cancer treatment landscape shifts from traditional to immune-targeted therapies, it’s important to understand the benefits and limitations of each approach. By examining the faces of immunotherapy, we can best understand how immunotherapy is changing the world.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]

The Old

  • Surgery
    Surgery can be used to completely remove or debulk a tumor.
  • Chemotherapy
    Chemotherapeutics are designed to kill fast-growing cells. These drugs can kill cancer cells but also kill or slow the growth of healthy cells.
  • Radiation
    Radiation therapy uses high doses of radiation to kill or slow the growth of cancer cells.

[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]

The New

  • Monoclonal Antibodies
    These drugs are designed to bind specific targets in the body.
  • Cancer Vaccines
    Vaccines expose the immune system to specific ‘antigens’. This triggers the immune system to recognize and destroy a specific target material.
  • Cell Therapies
    Cell-based immunotherapies aim to generate highly specific T cells that can recognize and eliminate cancer throughout the body.

[/vc_column_text][/vc_column][/vc_row][vc_row css=”.vc_custom_1474912818122{padding-top: 2px !important;}”][vc_column][vc_column_text]

Taking the Fight Directly to the Tumor

Intratumoral immunotherapies are administered directly to the tumor. One such approach is OncoSec’s ImmunoPulse® platform, which delivers DNA directly into tumor cells. This process is designed to stimulate the immune system to recognize and kill cancer cells. Their investigational therapy, ImmunoPulse® IL-12, harnesses the power of IL-12, a naturally occurring protein with immune-stimulating functions.

  • Over 70 patients treated to-date in multiple tumor types, including melanoma, breast cancer, head & neck cancer, and Merkel cell carcinoma
  • Positive clinical response and favorable safety profile observed across multiple trials
  • Data suggest ImmunoPulseTM IL-12 can generate an anti-cancer immune response and enhance response to other therapies

[/vc_column_text][/vc_column][/vc_row]